Results 101 to 110 of about 43,749 (262)

Cortisol as mineralocorticoid [PDF]

Journal of Clinical Endocrinology & Metabolism, 1996
openaire   +2 more sources

Triptolide capsule enables proteinuria reduction and renal stabilization in advanced alport syndrome beyond standard therapy

Rheumatology &Autoimmunity, EarlyView.
Zhuo‐ran Song, Na Li, Yang Li, Hong Zhang, Xu‐jie Zhou   +4 more
wiley   +1 more source

Hypercortisolism: Causes, Consequences and Clinical Significance – A Review of Pathophysiology

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Hypercortisolism or Cushing syndrome is a heterogeneous clinical spectrum caused by chronic glucocorticoid excess, ranging from exogenous Cushing syndrome to rare endogenous aetiologies and the increasingly recognised entity of mild autonomous cortisol secretion (MACS). Physiological cortisol production is tightly regulated by the hypothalamic–
Mohamed Eldib, Francisco Emilio Fierro, Maria Ortega Abad, Ricardo Correa   +3 more
wiley   +1 more source

How Common Is Hypercortisolism in Patients With Hypertension? Risk Factors, Epidemiology, and Making a Diagnosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target‐organ damage.
Omar Al Dhaybi, Deepak L. Bhatt
wiley   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess the feasibility of a decentralised response‐guided trial and to characterise urinary albumin‐to‐creatinine ratio (UACR) responses to empagliflozin and finerenone in type 2 diabetes and chronic kidney disease (CKD). Materials and Methods Adults with type 2 diabetes, estimated glomerular filtration rate (eGFR) ≥ 25 mL/min/1.73 m2,
Jelle M. Beernink, Gozewijn D. Laverman, Hiddo J. L. Heerspink   +2 more
wiley   +1 more source

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu, Chengsheng Ju, Stuart J. McGurnaghan, Luke A. K. Blackbourn, Scottish Diabetes Research Network Epidemiology Group, Peter Hanlon, Robert Lindsay, David McAllister, John Petrie, Naveed Sattar, Brian Kennon, Sam Philip, Scott Cunningham, Huan Wang, William Berthon, Helen Colhoun, Paul McKeigue, Sarah Wild, Ewan R. Pearson, Li Wei, Ruth Andrew   +20 more
wiley   +1 more source

Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study (MEDFINE‐RWD)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Although finerenone has shown efficacy in randomized trials, evidence from routine clinical practice remains limited. We aimed to assess the real‐world effectiveness and safety of finerenone in people with type 2 diabetes (PWT2D) and chronic kidney disease (CKD), with a particular focus on residual cardiorenal risk as reflected by changes ...
Oscar Moreno‐Pérez, Antonio Tejera‐Muñoz, Patricia Tomás‐Gómez, Federico Vázquez‐San Miguel, Virginia Soria‐Utrilla, Ada María Roldán‐Sánchez, Maya Sánchez‐Baya, Jersy Cárdenas‐Salas, Blanca Timón‐Vázquez, Juan J. Gorgojo‐Martínez, Ines Modrego‐Pardo, Irea Fernández‐Xove, Jose Carlos Fernández‐García, Rebeca Reyes‐García   +13 more
wiley   +1 more source

Is Hypercortisolism Treatable? Which Patients Should Be Treated and How—A Practical Guide for Clinicians

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To provide a practical guide on when to suspect endogenous hypercortisolism, how to use the overnight 1‐mg dexamethasone suppression test (DST) for targeted case‐finding, and which patients are most likely to benefit from treatment.
Juan Pablo Frias
wiley   +1 more source

Nonsteroidal Mineralocorticoid Receptor Antagonists in Heart Failure: Mechanistic Basis, Clinical Evidence, and Therapeutic Integration. [PDF]

Drugs Drug Candidates
Al-Horani RA, Goyal N.
europepmc   +1 more source